Efficacy and safety of deucravacitinib versus placebo in active psoriatic arthritis: a systematic review and meta-analysis
In brief
Deucravacitinib roughly doubles odds of arthritis response in psoriatic arthritis
In a review of three trials involving 1,430 adults, deucravacitinib about doubled the odds of reaching standard arthritis response thresholds versus placebo after 16 weeks, with improvements in skin disease, physical function, pain and other measures. Overall adverse events were similar between groups, but longer-term data and head-to-head trials are needed to show how it compares with other treatments.
- Journal
- Autoimmunity reviews (Q1)
- Published
- 12 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Syed Faqeer Hussain Bokhari, Ayesha Faheem, Sarah Ali, Maryum Choudhary, Samia Arif, Minahil Saif, et al.
- PMID
- 43020362
- DOI
- 10.1016/j.autrev.2026.104251
Why clinicians should know about it
- Picked for Dermatology (top studies of the week, 15 November 2026): Evaluates targeted TYK2 therapy and skin outcomes in psoriatic arthritis
Abstract
BACKGROUND: Deucravacitinib is a first-in-class selective TYK2 inhibitor approved for plaque psoriasis. No comprehensive systematic review and meta-analysis (SRMA) has evaluated its multidomain efficacy and safety in psoriatic arthritis (PsA). METHODS: We conducted a PRISMA compliant SRMA comparing deucravacitinib 6 mg once daily versus placebo in adults with active PsA. Effect sizes were expressed as odds ratios (OR) or mean differences (MD) with 95% confidence intervals. Heterogeneity was assessed using the I2 statistic and the certainty of evidence was graded using the GRADE framework. RESULTS: Three RCTs (N = 1430) were included, all rated low risk of bias. Deucravacitinib significantly outperformed placebo across all ACR response thresholds (ACR20: OR 2.07 [1.68-2.56]; ACR50: OR 2.13 [1.63-2.79]; ACR70: OR 2.42 [1.61-3.63]). Significant benefits were observed across composite disease activity indices including DAS28-CRP remission (OR 2.14 [1.62-2.82]) and DAPSA remission (OR 3.50 [2.04-6.00]), as well as minimal disease activity. Dermatological outcomes showed large treatment effects though with substantial heterogeneity. Significant improvements were also demonstrated in physical function, dactylitis resolution, disease-specific quality of life, fatigue, pain interference, and all four WPAI domains. The safety profile was comparable to placebo, with no significant differences in total adverse events (OR 1.30 [0.79-2.16]), serious adverse events (OR 1.00 [0.45-2.20]), or gastrointestinal events (OR 0.73 [0.42-1.25]). CONCLUSIONS: Deucravacitinib 6 mg once daily demonstrates consistent, multidomain superiority over placebo in active PsA at 16 weeks without excess adverse event burden. Head-to-head trials and longer-term data are needed to define its position in the treatment algorithm.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.